Indian stocks: Visit www.stage2stocks.com →

Sionna Therapeutics, Inc.

Stage 4 · Declining · week 10

As of Oct 22, 2026, Sionna Therapeutics is in Stage 4, the downtrend phase, now in week 10 (since Aug 14, 2026). It closed at $3.80, 92.6% below its 52-week high and below its 200-day average, which is falling.

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). More about the company

$3.80
-4.28% today
$172M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SION early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2025-02-07 → 2026-10-22
S? 41w
S2 13w
S3 10w
S2 8w
S4 10w
2025-02-072026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S2 13w → S3 10w → S2 8w → S3 2w → S2 4w → S3 1w → S4 10w current
Total tracked: 88 weeks across 8 stage runs.

SION among Biotechnology512th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…512SIONStage 4 · wk 107−31.0%
vs 52W High
-92.6%
$3.80 lo$51.04 hi
92.6% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 10
1w13w26w
Week 10, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-87.8%
200 DMA: $31.16 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.96x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-31.0%
3M
-91.7%
6M
-90.1%
YTD
-90.3%
1Y
-91.1%
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-22S4
Wk 10 · Vol 0.96x
2026-10-21S4
Wk 10 · Vol 0.68x
2026-10-20S4
Wk 10 · Vol 0.40x
2026-10-19S4
Wk 10 · Vol 0.43x
2026-10-16S4
Wk 9 · Vol 0.56x
2026-10-15S4
Wk 9 · Vol 0.35x
2026-10-14S4
Wk 9 · Vol 0.56x
2026-10-13S4
Wk 9 · Vol 0.30x
2026-10-12S4
Wk 9 · Vol 0.26x
2026-10-09S4
Wk 8 · Vol 0.24x
2026-10-08S4
Wk 8 · Vol 0.35x
2026-10-07S4
Wk 8 · Vol 0.34x
Moving averages & range
50 DMA
$5.72
200 DMA
$31.16
52W High
$51.04
52W Low
$3.80
5D Low
$3.80
Resistance levels (recent highs)
20d High
$5.26
60d High
$51.04
120d High
$51.04
250d High
$51.04
Next resistance
+38.4%
to 20d High
ROE
-32.3%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.6

Sionna Therapeutics: quick answers

What stage is Sionna Therapeutics in?

As of Oct 22, 2026, Sionna Therapeutics (SION) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 14, 2026 and is in week 10. What the four stages mean

Is Sionna Therapeutics in an uptrend?

No. Sionna Therapeutics is in a Stage 4 downtrend. It trades 87.8% below its 200-day average, which is falling.

How far is Sionna Therapeutics from its 52-week high?

Sionna Therapeutics closed at $3.80 on Oct 22, 2026, 92.6% below its 52-week high of $51.04. Its 52-week low is $3.80.

How has Sionna Therapeutics performed over the past year?

As of Oct 22, 2026, Sionna Therapeutics is down 91.1% over the past year and down 90.3% so far in 2026.

Which sector and industry is Sionna Therapeutics in?

Sionna Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.